164 / 280
38. Roca A, Sigaúque B, Quintó L, et al. Estimating
the vaccine-preventable burden of hospital-
ized pneumonia among young Mozambican
children.
Vaccine
. 2010;28(30):4851
–
4857
39. Cutts FT, Zaman SM, Enwere G, et al; Gam-
bian Pneumococcal Vaccine Trial Group.
Ef
fi
cacy of nine-valent pneumococcal con-
jugate vaccine against pneumonia and in-
vasive pneumococcal disease in The
Gambia: randomised, double-blind, placebo-
controlled trial.
Lancet
. 2005;365(9465):
1139
–
1146
40. Bhutta ZA, Das JK, Walker N, et al; Lancet
Diarrhoea and Pneumonia Interventions
Study Group. Interventions to address
deaths from childhood pneumonia and di-
arrhoea equitably: what works and at what
cost?
Lancet
. 2013;381(9875):1417
–
1429
(Continued from
fi
rst page)
PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).
Copyright © 2014 by the American Academy of Pediatrics
FINANCIAL DISCLOSURE:
In the tender for buying pneumococcal vaccine, Stockholm County Council included a demand that the company chosen to supply the
vaccine was to give the county a 5% discount off the vaccine price for enabling an epidemiological follow-up. Money from this discount has been used for the
current study. The money was not paid to an institution but directly to the Stockholm County Council.
FUNDING:
Supported by Stockholm County Council research funds, Foundation Samariten, Sachs
’
Children
’
s Hospital, Swedish Research Council, Swedish
Foundation for Strategic Research, Knut and Alice Wallenberg Foundation, and Sven Jerrings Foundation.
POTENTIAL CONFLICT OF INTEREST:
Dr Lindstrand received
fi
nancial contributions for participation in 2 scienti
fi
c conferences from GSK and P
fi
zer, and her
employer
fi
nanced the equivalent amount according to the national rules for pharmaceutical sponsorship for medical education, and she has participated in
1 clinical vaccine trial in collaboration with GSK.
LINDSTRAND et al
142